IP Library Granted Patent US 8,772,255
Granted Patent B2
US 8,772,255 · App. 12/053,486 · Granted Jul 8, 2014

Cell transfecting formulations of small interfering RNA related compositions and methods of making and use

Inventors: Timothy S. Burkoth (San Francisco, CA); Anne B. Jefferson (Oakland, CA); Christoph Reinhard (Alameda, CA); Ronald N. Zuckermann (El Cerrito, CA)
Assignee: Novartis Vaccines and Diagnostics, Inc.
C12N15/113A61K47/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,255
App. No.
12/053,486
Granted
Jul 8, 2014
Kind
B2
Abstract

Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.

Claims (16)

1. A method of inhibiting expression of a target gene in a subject, the method comprising administering to the subject a composition comprising:

a small interfering ribonucleic acid (siRNA) in a pharmaceutically acceptable delivery vehicle, wherein the delivery vehicle comprises a lipid-cationic peptoid conjugate of the formula:

L-X—[N(CH 2 CH 2 NH 2 )CH 2 (C═O)—N(CH 2 CH 2 R)CH 2 (C═O)—N(CH 2 CH 2 R)CH 2 (C═O)] 3 —NH 2

and positional isomers

where

L is selected from a non-sterol lipid moiety comprising at least one fatty alkyl or alkenyl chain between about 8 and 24 carbon atoms in length and a sterol moiety, wherein when L is a non-sterol lipid moiety, the peptoid conjugate is a lipitoid and when L is a sterol moiety, the peptoid conjugate is a cholesteroid;

each group R is independently selected from alkyl, aminoalkyl, and aralkyl, and

X is selected from the group consisting of a direct bond, an oligopeptide, a substantially linear alkyl chain from 2 to about 30 bonds in length, and a substantially linear chain from 2 to about 30 bonds in length consisting of alkyl bonds and one or more linkages selected from the group consisting of ester, amide, carbonate, carbamate, disulfide, peptide, and ether; wherein the delivery vehicle comprises a combination of lipitoid and cholesteroid peptoid conjugates; and

wherein one strand of the siRNA duplex has a nucleotide sequence comprised in an mRNA derived from the target gene.

2. The method of claim 1 , wherein the lipitoid:cholesteroid ratio is about 5:1 to 1:5.

3. The method of claim 2 , wherein the lipitoid:cholesteroid ratio is about 1:1 to 1:3.

4. The method of claim 3 , wherein the lipitoid is DMPE(NaeNmpeNmpe) 3 and the cholesteroid is Chol-β-ala-(NaeNmpeNmpe) 3 .

5. The method of claim 1 , wherein the siRNA comprises the sequence represented by SEQ ID NO: 1 with two nucleotide 3′-overhangs and phosphodiester link throughout.

6. The method of claim 1 , wherein the subject is a mammalian cell or cell line.

7. The method of claim 1 , wherein the subject is a mammal.

8. The method of claim 7 , wherein the subject is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2014
From: JEFFERSON, ANN B; ZUCKERMAN, RONALD N; REINHARD, CHRISTOPH; BURKHOTH, TIMOTHY S
To: CHIRON CORPORATION
Reel/Frame 032713/0153 →
MERGER Recorded Apr 19, 2014
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 032715/0219 →
Continuity (3)
Division 11018888 · Dec 20, 2004
Provisional Application 60530953 · Dec 19, 2003
Related Publication 20090143322A1 · Jun 4, 2009